Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience

QG D'Alessandris, N Montano, T Cenci, M Martini… - Acta …, 2013 - Springer
Background Advances in comprehension of molecular biology of glioblastoma (GBM) have
led to the development of targeted therapies. The aim of the present study was to evaluate …

Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience.

Q D'Alessandris, N Montano, T Cenci… - Acta …, 2013 - search.ebscohost.com
Background: Advances in comprehension of molecular biology of glioblastoma (GBM) have
led to the development of targeted therapies. The aim of the present study was to evaluate …

[PDF][PDF] Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience

QG D'Alessandris, N Montano, T Cenci, M Martini… - Acta …, 2013 - academia.edu
Background Advances in comprehension of molecular biology of glioblastoma (GBM) have
led to the development of targeted therapies. The aim of the present study was to evaluate …

Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience

N Montano, T Cenci, M Martini, L Lauretti… - Acta …, 2013 - search.proquest.com
Advances in comprehension of molecular biology of glioblastoma (GBM) have led to the
development of targeted therapies. The aim of the present study was to evaluate the efficacy …

Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience

QG D'Alessandris, N Montano, T Cenci, M Martini… - Acta …, 2013 - infona.pl
Background Advances in comprehension of molecular biology of glioblastoma (GBM) have
led to the development of targeted therapies. The aim of the present study was to evaluate …

Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience

N Montano, T Cenci, M Martini, L Lauretti… - ACTA …, 2012 - publicatt.unicatt.it
BACKGROUND: Advances in comprehension of molecular biology of glioblastoma (GBM)
have led to the development of targeted therapies. The aim of the present study was to …

Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience.

QG D'Alessandris, N Montano, T Cenci… - Acta …, 2012 - europepmc.org
Background Advances in comprehension of molecular biology of glioblastoma (GBM) have
led to the development of targeted therapies. The aim of the present study was to evaluate …

[PDF][PDF] Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience

QG D'Alessandris, N Montano, T Cenci, M Martini… - Acta …, 2013 - researchgate.net
Background Advances in comprehension of molecular biology of glioblastoma (GBM) have
led to the development of targeted therapies. The aim of the present study was to evaluate …

Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience

QG D'Alessandris, N Montano, T Cenci… - Acta …, 2013 - pubmed.ncbi.nlm.nih.gov
Background Advances in comprehension of molecular biology of glioblastoma (GBM) have
led to the development of targeted therapies. The aim of the present study was to evaluate …

[PDF][PDF] Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience

QG D'Alessandris, N Montano, T Cenci, M Martini… - Acta …, 2013 - academia.edu
Background Advances in comprehension of molecular biology of glioblastoma (GBM) have
led to the development of targeted therapies. The aim of the present study was to evaluate …